Advances in liver transplantation for unresectable colon cancer liver metastasis

Table 1 Published data on liver transplantation for colorectal cancer liver metastasis

Ref.	Year	Center	Period	Patients number	Survival time
Moore et al[12]	1964	Peter Bent Brigham Hospital, United States	September, 1963	1	11 d
Demirleau et al[58]	1964	Hospital St. Antonie, France	January, 1964	1	0 d (died of bleeding)
Andersen et al[59]	2012	Oslo University Hospital, Norway	1970	1	24 d (died of fuminating sepsis)
Penn[13]	1991	Cincinnati Medical Center, United States	September 1968-March 1991	8	Mortality 11% recurrence rate 70%
Pichlmayr et al[60]	1997	Hannover Medical School, German	1972-1995	4	11 mo, 8 d, 33 mo
Honoré et al[61]	2003	University of Liege, Belgium	1992	1	10 yr
Kappel et al[9]	2006	Medical University of Vienna, Austria	1983-1994	24	5-yr OS rate 12%-18%
Hoti et al[14]	2008	European Liver Transplant Registy	1968-1995	50 (including 24 above)	1- and 5-yr OS rate were 62% and 18%
Uskudar et al[62]	2011	The Mount Sinai Hospital, United States	2005, 2008	2	5 yr (no recurrence); 2 yr (no recurrence)
Kocman et al[63]	2011	University Hospital Mekur (Croatia)	2006	1	5 yr (no recurrence)
Hrehoreţ et al[64]	2013	University of Medicine and Phamarcy Caro Davila, Romania	January, 2012	1	20 mo post-operation (lung recurrence)
Line et al[46]	2015	Oslo University Hospital, Norway	2014-2017	3	40 d (died of complications); 5.5 yr (no recurrence); 2 yr (recurrent at 12 mo)
Caicedo et al[65]	2016	ICESI University, Colombia	November, 2014	1	19 mo (no recurrence)
Toso et al[66]	2017	Portugal, Paris, Geneva	1995-2015	12	5-yr OS 50% ± 16%, 5-yr PFS 38% ± 15%
Dueland et al[10]	2020	Olso University Hospital, Norway	2006-2012	23	5-yr OS 60%
Yang et al[67]	2019	Zhongnan Hospital of Wuhan University, China	2016	1	34 mo (recurrent at 4 mo)
Lerut et al[68]	2019	University Hospital Saint-Luc, Belgium	1985-2016	4	17 mo (recurrent at 6 mo), 64 mo (recurrent at 47 mo), 32 mo (no), 28 mo (recurrent at 4 mo)
Fernandes et al[69]	2019	Rio de Janeiro Federal University, Brazil	December, 2018	1	No prognosis information
Dueland et al[10]	2019	Oslo University Hospital, Norway	2012-2016	15	5-yr OS 83%
Smedman et al[25]	2019	Oslo University Hospital, Norway	2014-2018	10	Median OS 18 mo. Median DFS 4 mo
Coubeau et al[52]	2020	Cliniques Unviersitaires Saint-Luc	2019	1	180 d (no recurrence)

OS: Overall survival; DFS: Disease-free survival; PFS: Progression-free survival.